Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR t-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR t-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–32.

Article  CAS  PubMed  Google Scholar 

Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saez-Ibañez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022;21(9):631–2.

Article  PubMed  Google Scholar 

Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956.

Article  PubMed  PubMed Central  Google Scholar 

Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022;140(19):2024–36.

Article  CAS  PubMed Central  Google Scholar 

Liu A. CAR-T hype faces infrastructure reality check 2024 [Available from: https://www.fiercepharma.com/pharma/mid-decade-crisis-looms-car-t-cell-therapy.

Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024. https://doi.org/10.1084/jem.20230903.

Article  PubMed  PubMed Central  Google Scholar 

Liu A. J&J, Legend double CAR-T manufacturing investment to $500M as Carvykti eyes wider myeloma use 2022 [Available from: https://www.fiercepharma.com/manufacturing/legend-jj-double-down-car-t-manufacturing-500m-carvykti-eyes-wider-myeloma-use.

Wang Y, Tong C, Lu Y, Wu Z, Guo Y, Liu Y, et al. Characteristics of premanufacture CD8(+)T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):409.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017;8(8):573–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor NP. Allogene gets green light for pivotal CAR-T trial, starts industry's first off-the-shelf phase 2 2022 [Available from: https://www.fiercebiotech.com/biotech/allogene-gets-green-light-pivotal-car-t-trial-starts-industrys-first-shelf-phase-2.

Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697–705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jo S, Das S, Williams A, Chretien A-S, Pagliardini T, Le Roy A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun. 2022;13(1):3453.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies. Cancer Res. 2015;75(18):3853–64.

Article  CAS  PubMed  Google Scholar 

Sugita M, Galetto R, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, et al. Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat Commun. 2022;13(1):2227.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017. https://doi.org/10.1126/scitranslmed.aaj2013.

Article  PubMed  Google Scholar 

Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422–9.

Article  CAS  PubMed  Google Scholar 

Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J, et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol Ther. 2020;28(10):2237–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kath J, Du W, Martini S, Elsallab M, Franke C, Hartmann L, et al. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products. Blood Advances. 2023;7(15):4124–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li W, Zhu X, Xu Y, Chen J, Zhang H, Yang Z, et al. Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection. Front Immunol. 2022;13:1052717.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Degagné É, Donohoue PD, Roy S, Scherer J, Fowler TW, Davis RT, et al. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models. Cancer Immunol Res. 2024;12(4):462–77.

Article  PubMed  PubMed Central  Google Scholar 

Guo Y, Xu B, Wu Z, Bo J, Tong C, Chen D, et al. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis. Eur J Immunol. 2021;51(10):2513–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Tan B, Xing H, Zhao X, Ping Y, Zhang Z, et al. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies. Cancer Immunol Immunother. 2024;73(1):13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hammer Q, Perica K, Mbofung RM, van Ooijen H, Martin KE, Momayyezi P, et al. Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell Stem Cell. 2024;31(9):1376-86.e8.

Article  CAS  PubMed  Google Scholar 

Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023;14(1):2020.

Article  CAS  PubMed  PubMed Central  Google Scholar